Efficacy of extended ceftiofur intramammary therapy for treatment of subclinical mastitis in lactating dairy cows.
Little research has focused on treatment of cows with subclinical mastitis during lactation. Ceftiofur is a new broad-spectrum, third-generation cephalosporin antibiotic for veterinary use that inhibits bacterial cell wall synthesis by interfering with enzymes essential for peptidoglycan synthesis. Ceftiofur should be effective against a wide range of contagious and environmental mastitis pathogens. Objectives of the present study were to evaluate the efficacy of ceftiofur for treatment of subclinical mastitis in lactating dairy cows, and to determine if extended therapy regimens enhanced efficacy of ceftiofur. Holstein and Jersey dairy cows (n = 88) from 3 dairy research herds were used. Cows were enrolled in the study based on milk somatic cell counts >400,000/mL and isolation of the same mastitis pathogen in 2 samples obtained 1 wk apart. Cows with one or more intramammary infections (IMI) were blocked by parity and DIM and allocated randomly to 1 of 3 different ceftiofur treatment regimens: 2-d (n = 49 IMI), 5-d (n = 41 IMI), and 8-d (n = 38 IMI) treatment regimens. For all groups, 125 mg of ceftiofur hydrochloride was administered via intramammary infusion. Eighteen cows with 38 IMI were included as an untreated negative control group. A bacteriological cure was defined as a treated infected mammary quarter that was bacteriologically negative for the presence of previously identified bacteria at 14 and 28 d after the last treatment. Efficacy of ceftiofur therapy against all subclinical IMI was 38.8, 53.7, and 65.8% for the 2-, 5-, and 8-d ceftiofur treatment regimens, respectively. Four of 38 (10.5%) IMI in control cows were cured spontaneously without treatment. All 3 ceftiofur treatment regimens were significantly better than the negative control, and the 8-d extended ceftiofur treatment regimen treatment group was significantly better than the standard 2-d treatment group. Pathogen groups had significantly different cure rates from one another. The cure rate for the 8-d extended ceftiofur treatment regimen was 70% for Corynebacterium bovis, 86% for coagulase-negative Staphylococcus species, 36% for Staph. aureus, 80% for Streptococcus dysgalactiae ssp. dysgalactiae, and 67% for Strep. uberis.
Department of Animal Science and the Food Safety Center of Excellence, The University of Tennessee, Knoxville 37996, USA. soliver@utk.edu
S P
SP
Oliver
B E
BE
Gillespie
S J
SJ
Headrick
H
H
Moorehead
P
P
Lunn
H H
HH
Dowlen
D L
DL
Johnson
K C
KC
Lamar
S T
ST
Chester
W M
WM
Moseley
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002417:Cattle; D002452:Cell Count; D002511:Cephalosporins / Q000008:administration & dosage*; D003354:Corynebacterium Infections / Q000188:drug therapy / Q000662:veterinary; D005260:Female; D007774:Lactation; D008321:Mammary Glands, Animal / Q000187:drug effects*; D008414:Mastitis, Bovine / Q000188:drug therapy* / Q000382:microbiology; D008892:Milk / Q000166:cytology; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000662:veterinary; D013290:Streptococcal Infections / Q000188:drug therapy / Q000662:veterinary
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; C053503:ceftiofur